In the South and Central America pharmaceutical industry, there were six M&A deals announced in Q3 2024, worth a total value of $1.2bn, according to GlobalData’s Deals Database. The $1.2bn acquisition of Dermavant Sciences by Organon & Co was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q3 2024 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, M&A activity in South and Central America remained flat in Q3 2024 compared with the previous quarter and as compared to Q3 2023. Related deal volume increased by 100% in Q3 2024 versus the previous quarter and was 20% higher than in Q3 2023.
The top-ranked financial advisors supporting these M&A deals in South and Central America in 9M 2024 were Goldman Sachs Group; Lazard; Societe Generale with 1, 1, 1 deals respectively.
The top-ranked legal advisors supporting these M&A deals in South and Central America in 9M 2024 were Bird & Bird; Bredin Prat & Associates; Clifford Chance with 1, 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2024 – Strategic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.